Skip to content
Open access

CALR-mutated myeloproliferative neoplasms: Refining molecular risk beyond the driver.

Sep 2026 · British Journal of Haematology · 0 citations · 7 references
Medicine

TL;DR

Long-term data is provided across essential thrombocythaemia, post-ET myelofibrosis and primary MF, highlighting the prognostic relevance of additional somatic mutations in CALR-mutated myeloproliferative neoplasms.

Abstract

Calreticulin (CALR)-mutated myeloproliferative neoplasms (MPNs) are generally associated with favourable outcomes, yet considerable heterogeneity persists across the disease course. Mawalkar et al. provide long-term data across essential thrombocythaemia (ET), post-ET myelofibrosis (MF) and primary MF, highlighting the prognostic relevance of additional somatic mutations. The contribution of co-mutational context, variant allele frequency (VAF), disease origin and timing of molecular assessment remains incompletely defined. Commentary on: Mawalkar et al. Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms. Br J Haematol 2026 (Online ahead of print). doi: 10.1111/bjh.70859.

Read PDF

Similar papers

Open access Oct 2026

Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.

Calreticulin gene (CALR) mutations are seen in 25%-30% of myeloproliferative neoplasms (MPNs). We report outcomes and high-risk genomic signatures in 149 patients with CALR-mutated MPN. CALR-mutated essential thrombocythaemia (n = 106) progressed to myelofibrosis (n = 40) at a median of 20.4 years, and 20-year overall...

Resham Mawalkar, Hua-Ling Tsai, Sergiu-Vlad Paşca et al. · 1 citation
Open access Nov 2026

NPM1-mutated AML: One entity, multiple layers of heterogeneity.

Nucleophosmin 1 (NPM1) mutations are found in around one third of all acute myeloid leukaemias (AMLs). However, little is known about the clinical role of the rare, non-A NPM1 variants. Sangiorgio et al. showed that rare variants shared a similar molecular background and overall survival to the common type A, with FMS-...

M. Meggendorfer, W. Kern · 0 citations
Open access Oct 2026

EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study

Follicular lymphoma is the most common indolent lymphoma and next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D, CREBBP, and EZH2 ).

C. Martínez-Laperche, Pilar Lancho-Lavilla, Antonio Gutiérrez et al. · 0 citations
Review Open access Oct 2026

How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?

Myelofibrosis (MF), the most severe Philadelphia chromosome-negative myeloproliferative neoplasm, is driven by mutations in JAK2, CALR, or MPL, with CALR mutations accounting for 30-35% of cases. Mutant CALR forms an aberrant complex with the thrombopoietin receptor, resulting in constitutive JAK-STAT signalling and is...

Amy Mac Donald, Isaac Gannon, Elena Torre et al. · 0 citations
Review Open access Oct 2026

Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms

Simple Summary The classical BCR::ABL1 negative myeloproliferative neoplasms (MPN) are predominantly driven by mutations in three genes: JAK2, CALR, and MPL. Detection and quantitation of these mutations is important for disease diagnosis and monitoring. This review explores molecular methods used to monitor measurable...

Gary E. Markey, S. Langabeer · 0 citations
Review Nov 2026

Proliferative Leukoplakia.

Proliferative leukoplakia (PL) is an uncommon yet aggressive variant of oral leukoplakia characterized by its high rates of malignant transformation and recurrence. Primarily affecting older, non-smoking females, PL can present as homogenous, verrucous, or erythroleukoplakia lesions. PL is associated with high DNA aneu...

M. Alhadlaq, Lama Alabdulaaly, Sook-Bin Woo · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.